Gerald Borrelli, MD
Nephrology · Knoxville, TNNPI 1871599084
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,060 of the $189,714 with a category attached, or 90.7%. AstraZeneca accounts for 65.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $50,325 and has fallen 90.5% since, to $4,774 in 2025. Among nephrology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $574.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$123K
- Mallinckrodt Hospital Products Inc.$50K
- Mallinckrodt Enterprises LLC$15K
- Nxstage Medical, Inc.$328
- Amgen$300
- Fresenius USA Marketing, Inc.$223
- plus $710 from 11 others
What the payments were for
- Consulting fees$1,0601%
- Speaking & faculty fees$172,06091%
- Travel & lodging$10,4346%
- Food & beverage$5,9873%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 180 | $123,236 |
| Mallinckrodt Hospital Products Inc. | 66 | $49,863 |
| Mallinckrodt Enterprises LLC | 16 | $15,053 |
| Nxstage Medical, Inc. | 5 | $328 |
| Amgen(2 entities) | 15 | $300 |
| Fresenius USA Marketing, Inc. | 13 | $223 |
| Bayer | 3 | $151 |
| Akebia Therapeutics Inc | 5 | $117 |
| Travere Therapeutics, Inc. | 11 | $101 |
| Aurinia Pharma U.S., Inc. | 4 | $85 |
| Calliditas Therapeutics US Inc. | 2 | $59 |
| GSK | 2 | $44 |
| Novo Nordisk | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Sanofi | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$89,517
- ACTHAR$64,060
- FARXIGA$31,560
- LIBERTY SELECT CYCLER$233
- NXSTAGE SYSTEM ONE$233
- Kerendia$114
How this compares
$189,714 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 61 | $179,910 |
| FarxigaDapagliflozin Propanediol | 181 | $122,153 |
| AuryxiaFerric Citrate | 21 | $58,147 |
| JardianceEmpagliflozin | 67 | $52,795 |
| VeltassaPatiromer Calcium Sorbitex | 41 | $45,826 |
| LokelmaSodium Zirconium Cyclosilicate | 52 | $36,551 |
| DapagliflozinDapagliflozin Propanediol | 27 | $10,558 |
| KerendiaFinerenone | 14 | $10,102 |
| Sevelamer Carbonate | 84 | $9,191 |
| Calcium Acetate | 39 | $1,971 |
| Hydralazine Hcl | 97 | $1,649 |
| Labetalol Hcl | 43 | $911 |
| Calcitriol | 67 | $837 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 32 | $775 |
| Amlodipine Besylate | 136 | $673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $223 | $179,91061 claims |
| AstraZenecaFarxiga, Lokelma | $123,236 | $158,705233 claims |
| Akebia Therapeutics IncAuryxia | $117 | $58,14721 claims |
| BayerKerendia | $151 | $10,10214 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $26 | $9618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Knoxville
- Ross NesbitKnoxville$452K
- Jimmy GentryKnoxville$38K
- Ritu KhannaKnoxville$12K
- Urath SureshKnoxville$11K
- Kaitlin GreenKnoxville$6K
- Denise RiversKnoxville$4K
- Jamie DwyerNashville$461K
- Volker HaaseNashville$123K
- Chike NzerueCookeville$95K
- Talat IkizlerNashville$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.